Are You CovidMune?™
Covid-19 Clinical Trials Sampling
This represents a sampling of the first 30 clinical trials listed on clinical trials.gov specific to cover-19 investigations. Twenty out of the thirty proposed trials has
Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)
https://clinicaltrials.gov/ct2/show/NCT04333407?cond=COVID-19&draw=3&rank=15
Condition or disease COVID-19
Drug: Aspirin 75mg – 940 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=aspirin+and+NLRP3
Drug: Clopidogrel 75mg – 140 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Clopidogrel+and+NLRP3
Drug: Rivaroxaban 2.5 MG – 22 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Rivaroxaban+and+NLRP3
Drug: Atorvastatin 40mg – 528 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Atorvastatin+and+NLRP3
Drug: Omeprazole 20mg – 74 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Omeprazole+and+NLRP3
Duvelisib to Combat COVID-19
https://clinicaltrials.gov/ct2/show/NCT04372602?cond=COVID-19&draw=2&rank=1
Condition or disease COVID-19
Drug: Duvelisib – 2 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Duvelisib+and+NLRP3
Application of Desferal to Treat COVID-19
https://clinicaltrials.gov/ct2/show/NCT04333550?cond=COVID-19&draw=2&rank=3
Condition or disease COVID-19
Drug: Deferoxamine – 135 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Deferoxamine+and+NLRP3
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
https://clinicaltrials.gov/ct2/show/NCT04336904?cond=COVID-19&draw=2&rank=4
Condition or disease COVID-19
Drug: Favipiravir – 19 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Favipiravir+and+NLRP3
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression
https://clinicaltrials.gov/ct2/show/NCT04345445?cond=COVID-19&draw=2&rank=7
Condition or disease COVID-19
Drug: Tocilizumab – 307 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Tocilizumab+and+NLRP3
Drug: Methylprednisolone – 260 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Methylprednisolone+and+NLRP3
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
https://clinicaltrials.gov/ct2/show/NCT04359095?cond=COVID-19&draw=2&rank=8
Condition or disease COVID-19
Drug: Hydroxychloroquine – 254 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hydroxychloroquine+and+NLRP3
Drug: Lopinavir Pill – 48 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Lopinavir+and+NLRP3
Drug: Ritonavir Pill – 75 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Ritonavir+and+NLRP3
Drug: Azithromycin – 206 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Azithromycin+and+NLRP3
Isotretinoin in Treatment of COVID-19 (Randomized)
https://clinicaltrials.gov/ct2/show/NCT04361422?cond=COVID-19&draw=2&rank=9
Condition or disease COVID-19
Drug: Isotretinoin – 44 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Isotretinoin+and+NLRP3
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
https://clinicaltrials.gov/ct2/show/NCT04347915?cond=COVID-19&draw=2&rank=13
Condition or disease COVID-19
Drug: Clevudine – 2 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Clevudine+and+NLRP3
Drug: Hydroxychloroquine – 254 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hydroxychloroquine+and+NLRP3
Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection
https://clinicaltrials.gov/ct2/show/NCT04343183?cond=COVID-19&draw=2&rank=14
Condition or disease COVID-19
Device: Hyperbaric Oxygen Therapy – 169 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hyperbaric+Oxygen+and+NLRP3
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19
https://clinicaltrials.gov/ct2/show/NCT04291053?cond=COVID-19&draw=2&rank=17
Condition or disease COVID-19
Drug: Huaier Granule – 3 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Huaier+Granule+and+NLRP3
The Role of Resistant Starch in COVID-19 Infection
https://clinicaltrials.gov/ct2/show/NCT04342689?cond=COVID-19&draw=2&rank=19
Condition or disease COVID-19
Drug: Dietary Supplement containing resistant starch – 197 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=resistant+starch+and+NLRP3
Dietary Supplement: Placebo Starch – 105 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=placebo+starch+and+NLRP3
Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19 (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04336462?cond=COVID-19&draw=2&rank=18
Condition or disease COVID-19
Device: oxyhydrogen – no papers
Device: Oxygen – 11,740 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=oxygen+and+NLRP3
Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia
https://clinicaltrials.gov/ct2/show/NCT04363346?cond=COVID-19&draw=2&rank=21
Condition or disease COVID-1
Drug: FT516 (NK cells) – 5,110 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=NK+cells+and+NLRP3
DAS181 for Severe COVID-19: Compassionate Use
https://clinicaltrials.gov/ct2/show/NCT04324489?cond=COVID-19&draw=2&rank=22
Condition or disease COVID-19
Drug: DAS181 – 10 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=DAS181+and+NLRP3
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19 (ONSCOVID19)
https://clinicaltrials.gov/ct2/show/NCT04323228?cond=COVID-19&draw=2&rank=24
Condition or disease COVID-19
Dietary Supplement: oral nutrition supplement (ONS) enriched in
– eicosapentaenoic acid, – 428 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=eicosapentaenoic+acid+and+NLRP3
– gamma-linolenic acid and – 178 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=gamma-linolenic+acid+and+NLRP3
– antioxidants – 2,403 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=antioxidants+and+NLRP3
Study of
https://clinicaltrials.gov/ct2/show/NCT04335123?cond=COVID-19&draw=2&rank=27
Condition or disease COVID-19
Drug: Losartan – 206 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Losartan+and+NLRP3
Ivermectin and Nitazoxanide Combination Therapy for COVID-19
https://clinicaltrials.gov/ct2/show/NCT04360356?cond=COVID-19&draw=2&rank=29
Condition or disease COVID-19
Combination Product: Ivermectin – 58 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Ivermectin+and+NLRP3
plus Nitazoxanide – 28 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Nitazoxanide+and+NLRP3
Multi-site Adaptive Trials Using
https://clinicaltrials.gov/ct2/show/NCT04370262?cond=COVID-19&draw=2&rank=30
Condition or disease COVID-19
Drug: HCQ – Hydroxychloroquine – 254 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Hydroxychloroquine+and+NLRP3
+ Intravenous Famotidine – 11 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Famotidine+and+NLRP3
Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19 (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04376788?cond=COVID-19&draw=2&rank=26
Condition or disease COVID-19
Biological: exchange blood transfusion from normal donor
Biological: plasma from convalescent patients with COVID-19
Drug: Methylene Blue 5 MG/ML – 282 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=Methylene+Blue+and+NLRP3
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection
https://clinicaltrials.gov/ct2/show/NCT04354831?cond=COVID-19&draw=2&rank=6
Condition or disease COVID-19
Biological: anti-SARS-CoV-2 convalescent plasma – 84 papers on NLRP3
https://www.ncbi.nlm.nih.gov/pmc/?term=convalescent+plasma+and+NLRP3